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In every country, a manufacturer of medicinal products for either human or veterinary use is required to 
operate in compliance with local legislation. In all EU Member States, legislation is approximated to the 
effect that they are committed to abide by the same standards. The candidate countries transpose the acquis 
into their national legislation, including the good manufacturing practice (GMP). Consequently, the local 
manufacturer is required to strictly comply with GMP and the manufacturing licence, including for medicinal 
products exclusively intended for export. A vital role is also played by national regulatory authorities, in 
Croatia by the Agency for Medicinal Products and Medical Devices which issues the manufacturing licence, 
GMP certiﬁ cate, and the Certiﬁ cate of a Pharmaceutical Product (CPP) and conducts laboratory control of 
products. GMP inspection is carried out by the Pharmaceutical Inspectorate with the Ministry of Health 
and Social Welfare. Both authorities are responsible only for human medicines. There are legislative issues 
not yet harmonised with the acquis, but as a country aspiring for the EU membership, Croatia is expected 
to demonstrate that its industry and competent authorities are able to conform to current requirements and 
thus fully adhere to the integrated European regulatory network. Hence the importance of strengthening 
the institutional capacity of the competent authorities, as insufﬁ cient resources may have a direct bearing 
on patients by limiting their access to affordable treatment.
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Today we are facing difﬁ culties in securing a 
safe production and distribution chain for medicinal 
products. This is exempliﬁ ed by recent occurrences of 
contaminated heparin (1) causing severe anaphylactoid 
reactions, or the global recall of nelﬁ navir (Viracept®) 
due to contamination with ethyl methanesulfonate 
(2). Furthermore, the ever increasing presence 
of counterfeit medicines, also in the EU, poses a 
serious risk to public health (3, 4). Pharmaceutical 
manufacturers are obligated to apply GMP standards 
with strong emphasis on quality assurance and quality 
control (QA/QC) within the production process. Since 
the output is a human medicine, QA/QC procedures 
monitor and test the production process carefully 
to ensure that no patients will be harmed (5). The 
Croatian manufacturers and competent authorities 
are implementing the acquis which has been adopted 
into national legislation. In this pre-accession period 
there are still discrepancies in terms of the roles 
of manufacturers and the Agency responsible for 
medicines locally produced and those produced 
in other countries, including the EU (6). This 
article analyses the role of competent authorities, 
particularly of the Agency for Medicinal Products 
and Medical Devices (Agency), in the supervision of 
drug production and quality assurance, as well as the 
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role of the Pharmaceutical Inspectorate. The Agency 
is assigned the important task of granting GMP 
certiﬁ cates for products manufactured in Croatia, 
granting certificates of pharmaceutical products 
(CPPs), granting manufacturing licences to local 
manufacturers and withdrawing them when needed, 
and conducting quality control of products entering 
the country and retesting them by taking samples from 
pharmacy shelves.
GOOD MANUFACTURING PRACTICE
The concept of good manufacturing practice 
(GMP) is applied to any activities involving production 
management and operation. It is indispensable in 
pharmaceutical production, and its principles must be 
observed at all stages, from the production of active 
substances to the ﬁ nished product. Patients expect to 
get a safe, efﬁ cient and quality medicinal product (7, 8). 
GMP is intended to ensure drug production that would 
consistently meet all these requirements. Traditionally, 
drug manufacturers have relied on quality control 
(QC) procedures, based on the concept of testing the 
ﬁ nished product for compliance with speciﬁ cations, 
which in itself, however, is no guarantee that the 
product will possess the desired quality. For that 
reason, current procedures include quality assurance 
(QA) with emphasis on quality, from design to the 
ﬁ nished product. QA/QC are a part of GMP that 
provides efﬁ cacious drug production and distribution 
systems within an appropriate environment and by 
trained and qualiﬁ ed personnel.
Qualiﬁ ed personnel
A qualified personnel includes production 
operations and quality control people. In addition, 
the manufacturer is required to provide a sufﬁ cient 
number of trained quality assurance people. This 
in the ﬁ rst place refers to people qualiﬁ ed for batch 
(lot) release, as they issue certiﬁ cates for placing 
production batches on the market. Qualiﬁ ed person 
should be a university graduate educated in subjects 
speciﬁ ed in the Directive 2001/83/EC (9). In Croatia, 
these requirements best correspond to the Pharmacy 
Graduates, who are additionally specialised in drug 
testing and control for three years, or should have at 
least ﬁ ve-year experience in relevant jobs to qualify 
for such a position (6).The EU demands only two 
years of relevant experience. According to Croatian 
legislation (10) a qualiﬁ ed person for batch release 
in cases of the manufacture of speciﬁ c medicinal 
products (biologics, radiopharmaceuticals, medical 
gases) and pharmaceutical forms may also graduated 
in medicine, veterinary medicine, chemistry, biology 
and other scientiﬁ c disciplines, but should possess at 
last ﬁ ve-year experience in pharmaceutical quality 
control. The qualiﬁ ed person is a person responsible 
to release each batch of medicinal products for 
marketing (11).
Production premises and equipment
Production premises and equipment should be 
located, designed and managed in a way which will 
minimise the risk of error and facilitate efﬁ cient 
cleaning and maintenance with a view to avoiding 
contamination, cross contamination, and any other 
undesired effects on product quality. Likewise, 
premises and equipment used in production are 
critical for product quality and they should be properly 
qualiﬁ ed and validated (12).
Documentation
The manufacturer should establish and maintain 
a record-keeping system based on product quality 
requirements, pharmaceutical manufacturing 
formulations, manufacturing instructions, ﬁ nished 
pharmaceutical product packaging instructions, 
operating procedures, and records covering different 
production processes in order to demonstrate that 
operations are carried out in conformance with GMP. 
Records must be clear, without mistakes, and updated. 
Batch documentation should be kept for at least one 
year after the expiry date of the batch concerned or ﬁ ve 
years after placing a batch on the market, whichever 
comes later. Different production procedures should 
be carried out according to pre-established written 
instructions and procedures and in line with GMP. 
Any deviations from the established procedures 
and any damage to the product should be properly 
documented and thoroughly investigated. To avoid 
cross contamination or submixing, all necessary 
technical and organisational measures should be taken. 
Each new production procedure or major modiﬁ cation 
of the existing production procedure should be 
validated. The critical stages of a production procedure 
must be re-validated at regular intervals (13).
Process analytical technology
Process analytical technology (PAT) has been 
defined by the United States Food and Drug 
Administration (FDA) as a mechanism to design 
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and control pharmaceutical manufacturing processes 
through the measurement of critical quality parameters 
within given timeframes, aimed to assure the 
finished product quality. The PAT concept is 
aimed at understanding production by deﬁ ning its 
critical process parameters and by monitoring them 
(preferably in-line or on-line). This ensures greater 
testing efﬁ ciency, reduces over-processing, enhances 
consistency, and minimizes rejects. The concept is 
designed for the manufacturer to identify and measure 
all quality impact factors, so that the ﬁ nished product 
fulﬁ ls its pre-deﬁ ned characteristics from the start 
of production, which is also referred to as quality by 
design. Even though PAT activities are not a current 
requirement of the GMP in the EU, in 2003, the EMA 
created a forum for dialogue and understanding with 
the aim of reviewing the implications of PAT and 
ensuring that the European regulatory framework and 
authorities are prepared for and adequately equipped 
to conduct thorough and effective evaluations of 
PAT-based submissions. The EMA believes that the 
current regulatory framework in Europe is open to the 
implementation of PAT in marketing authorisation 
applications. Moreover, the International Conference 
on Harmonisation Guideline on Pharmaceutical 
Development (ICH Q8), which includes provisions 
on the use of PAT applications, has also been adopted 
by the EU.
Quality control
The manufacturer should establish and maintain 
a quality control system run by a qualiﬁ ed person 
independent of production. This person should have 
at his or her disposal one or more quality control 
laboratories staffed and equipped to test starting 
and packaging materials, intermediate and ﬁ nished 
products. To this end the services of other qualiﬁ ed 
laboratories may be used, i.e. those meeting GMP 
requirements, which are authorised in the procedure 
for granting the manufacturing license, and with which 
the manufacturer has a valid written contract. The ﬁ nal 
checking of ﬁ nished medicinal products, before placing 
them on the market, should take into account not only 
analytical results, but all other relevant information 
such as production conditions, results of process 
control, production documentation, and whether the 
product meets the set quality requirements, including 
its ﬁ nal packaging (14, 15).
Complaints and recalls
The manufacturer should establish a system of 
labelling and evaluating all complaints related to 
product defects and an efficient system to recall 
defective medicinal products. Finished products 
should be labelled and isolated pending checks for 
conformity to product speciﬁ cation. QA procedures 
should ensure that a defective ﬁ nished product is 
an exception. The manufacturer must notify local 
competent authorities and, if possible, the country of 
destination of any product defect that may result in its 
recall or in restricted application (16, 17).
Self-inspection
The QA system requires that the manufacturer 
monitors and oversees compliance with GMP and 
proposes measures to improve the QA system. Self-
inspection is internal and a record is kept for all 
inspections and corrective measures (18).
COMPETENT AUTHORITIES
Agency for Medicinal Products and Medical 
Devices
Competent authorities for GMP for medicinal 
products for human use in Croatia are the Agency 
for Medicinal Products and Medical Devices 
and the Ministry of Health and Social Welfare’s 
Pharmaceutical Inspection Department. The 
Agency grants the manufacturing license, certiﬁ cate 
of a pharmaceutical product (CPP), and good 
manufacturing practice certiﬁ cate (Figure 1) and the 
Ministry veriﬁ es compliance with GMP/GDP (Good 
Distribution Practice), Good Clinical Practice (GCP), 
Good Laboratory Practice (GLP), and conducts 
pharmacovigilance inspection.
Procedure for granting manufacturing licence
Manufacturing licence is not required for 
making extemporaneous and galenic formulations at 
pharmacies or laboratories, but it is for industrial drug 
production. Agency appoints a technical commission 
which makes an inspection to verify that the 
manufacturer meets GMP requirements. The technical 
commission consists of pharmaceutical inspectors and 
experts in relevant ﬁ elds. Pharmaceutical inspectors 
issue a written opinion based on inspection report 
and, in the event of deﬁ ciencies found at inspection, 
also based on the applicant’s response to the report. In 
its report, inspection encourages the manufacturer 
to set in motion its corrective and preventive 
action (CAPA) system. The aim of the CAPA 
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systems is to ensure that deﬁ ciencies/deviations/
non-conformance, product complaints, external 
and internal audit observations, annual product 
reviews, recommendations, and regulatory issues 
are identiﬁ ed, fully investigated to their root cause, 
and properly assessed by the manufacturer. If the 
applicant does not meet all the prescribed GMP 
requirements, the Agency may grant a temporary 
manufacturing licence for a term shorter than ﬁ ve 
years (6, 10).
GMP certiﬁ cate
The holder of the manufacturing licence may apply 
for a GMP certiﬁ cate that generally summarises the 
contents of the manufacturing license in one page. 
According to Croatian legislation, the issuance of the 
certiﬁ cate is subject to meeting GMP requirements laid 
down in the procedure of issuing the manufacturing 
licence or to a satisfactory on-site audit by the 
pharmaceutical inspector. However, Directive 2001/83/
EC (9) stipulates that an inspection is required before 
any GMP certiﬁ cate is granted. If inspection veriﬁ es 
GMP compliance, the certiﬁ cate is granted within 
90 days.
The certificate for a medicinal product or 
pharmaceutical form granted by the Agency speciﬁ es 
the place of production, production facility or 
facilities, and parts of the production process. GMP 
certiﬁ cate does certify manufacturer’s capability to 
maintain the consistency in the quality of an active 
pharmaceutical ingredient, so it is vital that on-site 
audits are performed. If an application for a GMP 
certiﬁ cate is submitted three years or more since the 
manufacturing licence was issued or since the latest 
audit was performed, the Agency will seek an opinion 
from the pharmaceutical inspectorate as to conﬁ rm 
whether GMP requirements have been met (10, 19).
Certiﬁ cate of a pharmaceutical product
The certiﬁ cate of a pharmaceutical product (CPP) 
is a voluntary certification scheme set up by the 
World Health Organization (WHO) and is issued by 
competent national authorities upon request from 
either the local manufacturer, the customer, or the 
authorities in the importing country. The certiﬁ cate is 
issued for a speciﬁ c product and indicates whether or 
not the product is marketed in the country of origin. 
Furthermore, it states that the manufacturer complies 
with GMP and that the pharmaceutical product 
is inspected regularly by the competent national 
authority. 
CPP issued by the Agency provides a partial 
assurance to countries with limited drug regulatory 
capacity that a pharmaceutical product which they plan 
to import is safe, effective, and of good quality.
Sampling and testing programme
Any medicinal product, either imported or locally 
manufactured, to be marketed in Croatia must hold the 
Agency’s marketing authorisation. The manufacturer 
Figure 1  Certiﬁ cates of a pharmaceutical product (CPP), good manufacturing practice certiﬁ cates (GMP) and manufacturing 
licenses granted by the Agency
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must ensure that all production procedures are in 
compliance with data submitted to the Agency when 
applying for marketing authorisation of a ﬁ nished 
product. Croatia-based manufacturers need to verify 
the quality of each batch of a ﬁ nished product that is 
to be released for marketing in Croatia. For ﬁ nished 
medicinal products imported to Croatia, it is the 
responsibility of the importer to verify that they 
comply with GMP. At the request of the competent 
authority, the importer must provide evidence that 
the product has been manufactured by a manufacturer 
holding the manufacturing licence. Both the local 
manufacturer and the importer are required to submit 
to the Agency samples of every ﬁ rst manufactured 
or imported batch for quality control. The Agency’s 
approval of every batch imported from the EU is 
based on a certiﬁ cate of analysis endorsed by a EU 
qualiﬁ ed person (QP) (Figure 2). Both the analysis 
of the ﬁ rst batch and the issuance of approval for 
imported batches from a single European market will 
cease to apply when Croatia becomes the EU member 
state, because they would be in contravention of the 
free movement of goods. Besides, medicinal products 
in the EU which are properly controlled and released 
for marketing by a QP do not have to be retested by 
any competent authority in the EU. Hence the Agency 
will steer its quality control towards the so-called risk-
based approach of taking samples from the market. 
This principle of off-the-shelf drug testing is also 
practised in this pre-accession period, where every 
medicinal product is taken off the shelves once in ﬁ ve 
years for testing by the Agency. In case of any doubt 
about the quality of a medicinal product or reported 
adverse effects, such a product may be ad hoc sampled 
and retested. If it is a third-country product, samples 
of each imported batch should be submitted to the 
Agency for testing (6).
The role of the inspector
GMP inspectors must be highly trained in all 
relevant areas of QA/QC management, production 
procedure, drug control, and distribution and 
inspection methodology (20). Apart from the EMA 
guidelines on the training and qualifications of 
GMP inspectors, each country may have additional 
requirements. In Croatia these are deﬁ ned by a special 
ordinance (21). It is desirable that an inspector has 
qualiﬁ cations as speciﬁ ed for the qualiﬁ ed person 
referred to in Directive 2001/83/EC (9) for human 
medicinal products and in Directive 2001/82/EC (22) 
for veterinary medicinal products. It is necessary to 
constantly assess the educational needs of inspectors 
and take steps to improve their skills. Organisationally, 
the GMP inspectorates in the Member States, with the 
exception of Germany, The Netherlands, and Poland, 
are attached to the national medicines agencies, 
Figure 2 Batch release of locally manufactured and imported batches in Croatia according to local legislation (6)
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which makes them a constituent part of an integrated 
regulatory system. In Croatia, the Agency is responsible 
for the issuance of manufacturing licences, GMP and 
CPP certiﬁ cates, whereas the GMP audit itself is the 
responsibility of the Pharmaceutical Inspectorate of the 
Ministry of Health and Social Welfare. Furthermore, 
the Inspectorate for Veterinary Medicinal Products is 
part of the Veterinary Directorate at the Ministry of 
Agriculture, Forestry and Rural Development. The 
inspectorate for human medicines performs regular 
and extraordinary inspections of drug manufacturers. 
Regular inspections are performed every two to three 
years. Extraordinary inspections are undertaken in 
case of incident situations, serious complaints, product 
recalls, product defects detected by the Agency, doubts 
about product quality or signs of unusual occurrences 
and other circumstances, with an aim to ensure product 
quality. Serious non-compliance by deﬁ nition requires 
administrative action to be taken by the inspector.
Quality defects and batch recalls
Every health care professional, physician, or 
pharmacist is required to report a defective medicinal 
product to the Agency, which, depending on the degree 
of urgency, takes appropriate action that may include 
recalling the product from the market (23). Batches or 
marketing authorisation may also be suspended due 
to pharmacovigilance issues, where an unexpected 
signal of an adverse drug reaction or unexpected 
grouping of signals linked to certain batches occurs. 
Every marketing authorisation holder in Croatia 
should have in place an efficient product recall 
procedure and report recall to the Agency and relevant 
authorities in other countries. The Agency informs 
the public and health care services about the recall of 
defective products on its web pages and through the 
National Information Centre, which is responsible for 
immediately informing hospitals and other health care 
institutions. In 2009, only ﬁ ve batches were recalled 
from the Croatian market, compared with 15 in 2007. 
In most cases, however, product batches are recalled 
by the manufacturer himself, who notiﬁ es the Agency 
of suspected defects.
INTERNATIONAL CO-OPERATION
European Economic Area (EEA)
The European Medicines Agency (EMA) is 
responsible for the maintenance and public release of 
the collection of European inspection procedures and 
exchange of information. Under Directive 2003/94/EC 
(24) all Member States are committed to take these 
procedures as a basis for standard operative procedures 
within their GMP inspectorates. According to 
Directives 2001/83/EC, 2001/82/EC and 2001/20/EC 
(9, 22, 25), an inspector of a Member State competent 
authority inspects on behalf of the entire EU and these 
inspections are supposed to be mutually recognised by 
all Member States. Information obtained during GMP 
inspections should be kept conﬁ dential by inspectors, 
in accordance with the EU, national, and international 
laws and agreements. Inspections by a Member State 
competent authority are carried out on behalf of the 
entire EU, because GMP non-compliance may have an 
impact on other Member States. Competent national 
authorities must take into account information on 
serious GMP non-compliance received and should 
follow recommended actions, where the procedures 
requires to do so, unless their competent authorities 
can justify alternative courses of action based on 
speciﬁ c national considerations, provided that they 
have no impact on other Member States. With regard 
to actions, direct or consequential, against marketing 
authorisations, the Reference Member State1 takes 
initiative for mutual recognition. EMA co-ordinates 
action regarding centrally authorised products. Each 
competent national authority takes the responsibility 
for marketing authorisations on national level alone. 
The reporting inspectorate should enter information 
on serious GMP non-compliance in the Eudra GMP 
telematic system. The procedure requires that the 
inspectorate discovering serious GMP non-compliance 
should recommend appropriate action, involving other 
authorities that share supervisory responsibility in 
developing such recommendations, and communicate 
their recommendations to all other authorities in the 
EU, European Directorate for the Quality of Medicines 
and Health Care (EDQM), and to countries that have 
signed a mutual recognition agreement (MRA), 
Pharmaceutical Inspection Convention / Scheme 
(PIC/S), (26, 27) and New Collaboration Agreement 
between Drug Regulatory Authorities in Central and 
Eastern Europe (nCADREAC).
1 EU Member State responsible for drafting the assessment report in the 
decentralised or mutual recognition procedure for granting marketing 
authorisation for a medicinal product
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European Directorate for the Quality of Medicines 
and Health Care
European Directorate for the Quality of Medicines 
and Health Care (EDQM) issues the Certiﬁ cate of 
European Pharmacopoeia (CEP), established in 
1994. Initially it was limited to active substances, but 
since 1999 it has included products that pose a risk 
of transmissible spongiform encephalopathy (TSE). 
This certiﬁ cation procedure ensures the quality of 
active substances and excipients and conformance to 
the European Pharmacopoeia. When applying for a 
marketing authorisation, the applicant may use CEP 
as a proof that the used substance conforms to the 
European Pharmacopoeia. Suspension or voiding 
of a CEP may be a recommended course of action 
following an inspection by EDQM of an active 
substance manufacturer who does not conform to 
GMP standards anymore. This procedure additionally 
addresses action to be taken by both manufacturers and 
regulators in the event of notiﬁ cation by EDQM that 
a CEP has been voided or suspended (28). There are 
procedural differences in suspension or cancellation 
of certiﬁ cates between EDQM and FDA. If EDQM 
ﬁ nds that an active pharmaceutical ingredient API 
fails to meet GMP requirements, it will set up an 
ad hoc committee to decide on CEP suspension. If 
FDA ﬁ nds non-compliance, it will ﬁ le a report on 
which the manufacturer must state its position. If the 
manufacturer’s answers remain unsatisfactory, FDA 
will send him a warning letter. These two approaches 
demonstrate differences between the EU and US 
regulatory systems, where the latter decides based 
upon the manufacturer’s statement, whereas in the EU, 
manufacturer is not involved in decision-making, but 
the decision is made by regulators alone.
Pharmaceutical Inspection Convention / Scheme
Pharmaceutical Inspection Convention (PIC) was 
established by the European Free Trade Association 
(EFTA) in 1970. It was an international treaty between 
Table 1 Local pharmaceutical manufacturers in Croatia
Manufacturer Pharmaceutical forms/procedures Manufacturing site
Belupo lijekovi i kozmetika d.d.




primary packaging, quality control, stocking, 
delivery
Zagreb
Croatian Institute for 
Transfusion Medicine
solutions for infusions, concentrates for solutions 
for infusion, solutions for injections
Zagreb, Hrvatski Leskovac 
Farmal d.d.




primary packaging, quality control, stocking, 
delivery tablets, effervescent tablets, granules, 
powders, solutions, gels, shampoos
Rakitje
Fitofarmacija d.o.o.




primary packaging, quality control, stocking, 
delivery
Zagreb
Imunološki zavod d.d./Institute 
of Immunology 





sterile solutions, non-sterile solutions, solid 




primary packaging, quality control, stocking, 
delivery
Jastrebarsko
Lukaps d.o.o. hard gelatine capsules Ludbreg
Messer Croatia Plin d.o.o. medicinal oxygen Zaprešić
PharmaS d.o.o.




active pharmaceutical ingredient, sterile solutions, 
solid oral forms
Zagreb, Savski Marof
Ruđer Medikol Ciklotron d.o.o. radiopharmaceuticals Zagreb
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participating countries, whose main goal was to 
harmonise GMP rules and the inspection system, and 
to mutually recognise pharmaceutical reports and 
inspectors’ qualiﬁ cations between the participants. By 
1992, PIC had 18 members, largely from the EU. Since 
1992 however, the only body authorised to negotiate 
international treaties, including mutual recognition 
between the third countries and Member States has 
been the European Commission, and PIC became 
unsustainable. For this reason, PIC has switched 
from an international treaty to a more ﬂ exible form 
of integration of GMP inspection authorities. The 
result is the Pharmaceutical Inspection Convention 
/ the Pharmaceutical Inspection Co-operation 
Scheme (PIC/S). Today PIC/S brings together 37 
inspection authorities, mostly from the EU Member 
States. Applications for PIC/S membership have 
been submitted by the competent authorities of 
Saudi Arabia, Bulgaria, China, Croatia, Iran, The 
Philippines, Serbia, and the USA. It happens every so 
often that inspection reports ﬁ led by a PIC/S member 
are used by others in planning inspections based on 
risk management. PIC/S is not committed to mutual 
recognition of inspection reports by its members, but 
does encourage that (29).
DISCUSSION
In Croatia several manufacturers make medicinal 
products for human use in a variety of pharmaceutical 
forms, including capsules and tablets, semi-solid 
emulsions, parenteral solutions, lyophilised powders 
for intravenous and intramuscular administration, 
syrups, suspensions, and drops (Table 1). These 
are medicines of all therapeutic groups, plus 
vaccines, blood components, and medicinal gases. 
Pharmaceutical industry in Croatia is largely generic, 
that is, it makes products similar to the ones whose 
patent protection has expired. With the exception of 
azithromycin, local manufacturers mainly import 
active substances and even ﬁ nished formulations, and 
it is essential to make sure that GMP is maintained. 
Local manufacturers receive the manufacturing 
licence from the Agency for all sites in Croatia where 
their production takes place. Furthermore, the Agency 
issues GMP and CPP certiﬁ cates upon request. These 
primarily serve for the export of individual batches 
abroad. Figure 1 shows that the number of issued 
GMP and CPP certiﬁ cates dropped in 2009, which 
can be associated with recent acquisitions in Croatia 
that resulted in changes to the existing production 
portfolio of manufacturers. It is possible that the 
growth of issued GMP/CPP certificates depends 
on the vitality of the local pharmaceutical industry. 
Meanwhile, the number of issued production licences 
was increased, resulting from new generic drug 
companies that arose as greenﬁ eld investments in 
Croatia. Frequent variations in manufacturing license 
are an administrative burden, as the license in Croatia 
is granted for a medicinal product under the trade 
name, and not for a pharmaceutical form alone, which 
would be easier to handle, like in the EU countries. 
Globalisation and mere survival on the market push 
local manufacturers to export and therefore meet 
inspection requirements of other EU and non-EU 
countries (30). For export to the EU countries it is 
necessary to obtain the EU GMP certiﬁ cate, and 
Croatian manufacturers are for that purpose subject to 
inspection by Member State inspectorates. In Croatia, 
competence over GMP inspection and regulation 
is now split between the Ministry and the Agency, 
whereas in most countries it is a regulatory matter of 
the Agencies. If GMP inspection were to become the 
Agency’s responsibility, certain administrative and 
other decisions would be easier to make, because 
the Agency has complete documentation about 
medicines and production and experts to evaluate 
medicinal products. Croatian inspectors participate 
in some of the meetings of EMA’s GMP Inspectors 
Group and EudraGMP Telematics Groups, although 
in terms of preparation for EU membership they 
would beneﬁ t much more from ﬁ eld team training 
with their colleagues from the EU. For Croatia, PIC/S 
membership would contribute to the promotion of 
mutual exchange of information and resources.
Considering that most of active substance 
production has moved to lower-cost geographies, 
where it is not necessarily supervised by health 
authorities and where the likelihood of substandard 
medicines entering the supply chain is greater, it is 
necessary to inspect the place of active substance 
production in third countries (31). Therefore, Croatian 
legislation will need additional provisions to deﬁ ne 
the inspection of active substance manufacturers 
by the national authority. According to the current 
legislation, the Agency may inspect manufacturing 
sites abroad if that is necessary during the marketing 
authorisation procedure. However, inspection of 
active substance manufacturers will require further 
training of inspectors. This will facilitate exchange 
of information and mutual recognition of active 
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substance inspection reports between Croatia and 
regulators in the integrated European network.
It is also important that Croatia is included in the 
Rapid Alert System before joining the EU in order to 
make the exchange of relevant and urgent information 
as quick as possible.
Croatia has local production of vaccine and blood 
components, including integrated active substance 
production. Vaccine manufacturing standards have 
been raised high and production requires strict 
supervision by the Agency. For vaccine manufacturers 
in developing countries the only possibility of 
survival on the international market is the WHO 
Prequalification Programme, which includes a 
positive assessment of both the manufacturer and 
the competent authority (32), one that the Croatian 
Agency has already obtained. Local manufacturers 
have a qualiﬁ ed person on staff and release batches 
to the Croatian market, with the exception of the 
ﬁ rst production batch which may only be released 
to the market following analyses conducted by the 
Agency. If the intent is to export the product to the 
territory of the EU/EEA, the manufacturer must have 
a qualiﬁ ed person for batch release there. Considering 
that Croatia is not yet a full member of the European 
Union, drug batches imported from the EU may not 
be automatically released on the Croatian market. 
However, in light of joining the common European 
market where all barriers to the free movement of 
goods will be eliminated and in light of the fact that 
no national agency can conduct a complete batch 
release analysis for each imported batch, the Agency 
advocates administrative release of batches imported 
from the EU in the manner that an analysis is not 
conducted, but instead the certiﬁ cate of analysis and 
the content of the sales presentation are inspected for 
each imported batch. Pursuant to these, approval is 
granted for the import of the drug and batch release for 
the Croatian market. However, drug importers from 
the third countries are required to undergo Agency 
analysis for each imported batch (Figure 2).
CONCLUSION
As local manufacturers increase export, so does 
Agency’s monitoring activity become increasingly 
internationalised. Besides, both the Agency and the 
manufacturers are adapting to market conditions that 
will prevail once Croatia becomes part of the single EU 
market. To this end, both sides are implementing EU 
Directives that Croatia has adopted and incorporated 
into its national legislation. As we move forward, it 
will become increasingly important to produce well 
trained inspectors. Every country has its own GMP 
rules. As regards inspections, what matters most is 
their regularity, efﬁ cacy in enforcing GMP, and quick 
reporting on non-compliance. Croatia’s accession to 
full membership of the European regulatory network, 
which promotes exchange of information and 
resources in the area of GMP and provides education 
for inspectors, will give a new boost to our ﬁ ght against 
pharmaceutical counterfeiting as a global problem 
and our to strivings to protect patients. Moreover, 
international co-operation is heading towards a global 
inspection framework. The new European legislation 
in the pipeline will place greater direct responsibility 
on the manufacturer.
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Sažetak
DOBRA PROIZVOĐAČKA PRAKSA: ULOGA DOMAĆIH PROIZVOĐAČA I NADLEŽNIH 
TIJELA
U svakoj zemlji proizvođač lijekova za humanu ili za veterinarsku uporabu obavezan je poslovati sukladno 
lokalnom zakonodavstvu, koje je u EU usklađeno za sve članice koje moraju poštivati jednake standarde. 
Zemlje kandidati za članstvo ugrađuju europsko zakonodavstvo u nacionalno i na taj način implementiraju 
dobru proizvođačku praksu (GMP). Sukladno tomu, proizvođač lijeka obvezan je osigurati da se svi 
proizvodni postupci za lijekove izvode u skladu s dobrom proizvođačkom praksom i proizvodnom dozvolom 
uključujući i lijekove koji su namijenjeni samo za izvoz. Ovdje je nezaobilazna i uloga nacionalnih 
regulatornih tijela posebno Agencije za lijekove i medicinske proizvode koja izdaje proizvodnu dozvolu, 
GMP certiﬁ kate i certiﬁ kate o farmaceutskom proizvodu - lijeku (CPP) te provodi laboratorijsku kontrolu 
proizvoda. GMP inspekciju provodi farmaceutski inspektorat koji je u sastavu Ministarstva zdravstva i 
socijalne skrbi. Oba su tijela nadležna samo za lijekove za humanu uporabu. Postoje još neka neusklađena 
pitanja što se tiče prihvaćanja Pravne stečevine na ovome polju, ali kako je Hrvatska zemlja kandidat za 
punopravno članstvo u EU, očekuje se da će moći demonstrirati da njezina industrija i nadležna tijela 
poštuju važeće zahtjeve EU i tako potpuno pristupaju europskoj regulatornoj mreži. Stoga je važno jačati 
institucionalni kapacitet nadležnih tijela, jer nedostatni potencijali mogu izravno utjecati na pacijente 
ograničavajući im pristup dostupnim terapijama.
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